Levocetirizine: Pharmacokinetics and pharmacodynamics in children age 6 to 11 years

被引:39
作者
Simons, FER
Simons, KJ
机构
[1] Univ Manitoba, Fac Med, Canadian Inst Hlth Res, Natl Training Program Allergy & Asthma,Dept Immun, Winnipeg, MB R3T 2N2, Canada
[2] Univ Manitoba, Fac Med, Fac Pharm, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada
关键词
H-1-antihistamine; levocetirizine; pharmacokinetics; pharmacodynamics; wheal; flare; allergic rhinitis; urticaria; children;
D O I
10.1016/j.jaci.2005.04.010
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: The pharmacokinetics and pharmaeodynamics of medications may differ between children and adults, necessitating different dose regimens for different age groups. Levocetirizine, the active enantiomer of cetirizine, is used in the treatment of allergic rhinitis and chronic urticaria in Europe. Its pbarmacokinetics and pharmacodynamics have not yet been studied prospectively in school-age children. Objectives: This study was performed to investigate levocetirizine pharmacokinetic disposition and pharmacodynamics in relation to skin reactivity to histamine in children aged 6 to 11 years. Methods: Blood samples were obtained at predose baseline and at defined intervals up to and including 28 hours after a 5-mg levocetirizine dose. Concurrently, epicutaneous tests with histamine phosphate, 1 mg/mL, were performed. Wheals and flares were traced at 10 minutes, and the areas were measured with a computerized digitizing system. Results: In children aged 8.6 +/- 0.4 years (+/- SEM), the peak levocetirizine concentration was 450 +/- 37 ng/mL, and the time at which peak concentrations occurred was 1.2 +/- 0.2 hours. The terminal elimination half-life was 5.7 +/- 0.2 hours, the oral clearance was 0.82 +/- 0.05 mL/min/kg, and the volume of distribution was 0.4 +/- 0.02 L/kg. Compared with predose areas, the wheals and flares produced by histamine phosphate were significantly decreased from 1 to 28 hours, inclusive (P < .05). Mean maximum inhibition of wheals and flares occurred from 2 to 10 hours (97% +/- 1%) and from 2 to 24 hours (93% +/- 1%), respectively. Conclusions: Levocefirizine had an onset of action within I hour and provided significant peripheral antihistamirtic activity for 28 hours after a single dose. Once-daily dosing may be optimal in children aged 6 to 11 years, as it is in adults.
引用
收藏
页码:355 / 361
页数:7
相关论文
共 31 条
[1]   Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis [J].
Bachert, C ;
Bousquet, J ;
Canonica, GW ;
Durham, SR ;
Klimek, L ;
Mullol, J ;
Van Cauwenberge, PB ;
Van Hammée, G .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (04) :838-844
[2]   Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers [J].
Baltes, E ;
Coupez, R ;
Giezek, H ;
Voss, G ;
Meyerhoff, C ;
Benedetti, MS .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 (04) :269-277
[3]  
Benedetti MS, 2001, EUR J CLIN PHARMACOL, V57, P571
[4]   Efficacy, safety and pharmacokinetics of levocetirizine in allergic children aged 1-2 years. [J].
Cranswick, NE ;
Fuchs, M ;
Turzikova, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) :P46-P46
[5]   A PHARMACOKINETIC EVALUATION OF THE 2ND-GENERATION H-1-RECEPTOR ANTAGONIST CETIRIZINE IN VERY YOUNG-CHILDREN [J].
DESAGER, JP ;
DAB, I ;
HORSMANS, Y ;
HARVENGT, C .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (04) :431-435
[6]   A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers [J].
Devalia, JL ;
De Vos, C ;
Hannotte, F ;
Baltes, E .
ALLERGY, 2001, 56 (01) :50-57
[7]   UNDERSTANDING THE DOSE-EFFECT RELATIONSHIP - CLINICAL-APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELS [J].
HOLFORD, NHG ;
SHEINER, LB .
CLINICAL PHARMACOKINETICS, 1981, 6 (06) :429-453
[8]   Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine:: the ETAC® study [J].
Hussein, Z ;
Pitsiu, M ;
Majid, O ;
Aarons, L ;
de Longueville, M ;
Stockis, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (01) :28-37
[9]   Developmental pharmacology - Drug disposition, action, and therapy in infants and children [J].
Kearns, GL ;
Abdel-Rahman, SM ;
Alander, SW ;
Blowey, DL ;
Leeder, JS ;
Kauffman, RE .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (12) :1157-1167
[10]  
Lin Chin-Chung, 1995, Am J Ther, V2, P504, DOI 10.1097/00045391-199506000-00011